Company intelligence / Profile preview

Forsite Diagnostics

Boulder, Colorado, United States

Ownership: Private
Development stage: Other

Overview

Foresight has validated its minimal residual disease (MRD) technology in thousands of patient samples across multiple cancer types, with over 30 peer-reviewed publications and 25+ academic and biopharma partnerships demonstrating ultra-sensitive ctDNA detection below conventional detection limits.

Therapeutic areas: Oncology
Modalities: Liquid biopsy
Industry: Molecular Diagnostics

Partnerships

Over 25 academic and biopharma partnerscollaborations include clinical program development and drug development acceleration

Beyond the preview

Go deeper on Forsite Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Forsite Diagnostics.

Explore the full profile